Enhancement of Hemocompatibility of the MERA Monopivot Centrifugal Pump: Toward Medium‐Term Use

The MERA monopivot centrifugal pump has been developed for use in open‐heart surgery, circulatory support, and bridge‐to‐decision for up to 4 weeks. The pump has a closed‐type, 50‐mm diameter impeller with four straight paths. The impeller is supported by a monopivot bearing and is driven by a radial‐flux magnet‐coupling motor. Because flow visualization experiments have clarified sufficient pivot wash and stagnation at the sharp corner of the pivot support was suggested, sharp corners were removed in the design stage. The index of hemolysis of the pump operating at more than 200 mm Hg was found to be lower than that of a commercial pump. Four‐week animal tests were then conducted two times; improvement of thrombus formation was seen in the female pivot through modification of female pivot geometry. Overall antithrombogenicity was also recorded. Finally, to assure mid‐term use, an additional 4‐week durability test revealed that the rate of the axial pivot wear was as small as 1.1 µm/day. The present in vitro and in vivo studies revealed that the MERA monopivot centrifugal pump has sufficient hemocompatibility and durability for up to 4 weeks.